Literature DB >> 17021907

The changing face of prostate cancer: can gains in epigenetic knowledge translate into improvements in clinical care?

James W F Catto1.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 17021907     DOI： 10.1007/s00109-006-0110-0

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN： 0946-2716            Impact factor:   4.599


× No keyword cloud information.
  17 in total

1.  Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.

Authors:  D Dhawan; F C Hamdy; I Rehman; J Patterson; S S Cross; K M Feeley; Y Stephenson; M Meuth; J W F Catto
Journal:  J Pathol       Date:  2006-07       Impact factor: 7.996

2.  Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.

Authors:  Eli Rosenbaum; Mohammad Obaidul Hoque; Yoram Cohen; Marianna Zahurak; Mario A Eisenberger; Jonathan I Epstein; Alan W Partin; David Sidransky
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

3.  Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines.

Authors:  M F Kane; M Loda; G M Gaida; J Lipman; R Mishra; H Goldman; J M Jessup; R Kolodner
Journal:  Cancer Res       Date:  1997-03-01       Impact factor: 12.701

4.  Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.

Authors:  Rui Henrique; Vera Lúcia Costa; Nuno Cerveira; André Lopes Carvalho; Mohammad Obaidul Hoque; Franclim Ricardo Ribeiro; Jorge Oliveira; Manuel Rodrigues Teixeira; David Sidransky; Carmen Jerónimo
Journal:  J Mol Med (Berl)       Date:  2006-09-22       Impact factor: 4.599

Review 5.  Epigenetic changes in prostate cancer: implication for diagnosis and treatment.

Authors:  Long-Cheng Li; Peter R Carroll; Rajvir Dahiya
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

6.  Neuro-fuzzy modeling: an accurate and interpretable method for predicting bladder cancer progression.

Authors:  James W F Catto; Maysam F Abbod; Derek A Linkens; Freddie C Hamdy
Journal:  J Urol       Date:  2006-02       Impact factor: 7.450

7.  Global histone modification patterns predict risk of prostate cancer recurrence.

Authors:  David B Seligson; Steve Horvath; Tao Shi; Hong Yu; Sheila Tze; Michael Grunstein; Siavash K Kurdistani
Journal:  Nature       Date:  2005-06-30       Impact factor: 49.962

8.  Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.

Authors:  James W F Catto; Abdel-Rahmene Azzouzi; Ishtiaq Rehman; Kenneth M Feeley; Simon S Cross; Najla Amira; Gaelle Fromont; Mathilde Sibony; Oliver Cussenot; Mark Meuth; Freddie C Hamdy
Journal:  J Clin Oncol       Date:  2005-03-07       Impact factor: 44.544

9.  Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma.

Authors:  Susan V Harden; Zhongmin Guo; Jonathan I Epstein; David Sidransky
Journal:  J Urol       Date:  2003-03       Impact factor: 7.450

10.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245
View more
  1 in total

1.  BPH and prostate cancer risk.

Authors:  Saiful Miah; James Catto
Journal:  Indian J Urol       Date:  2014-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.